Thermo Fisher Builds Pharmaceutical Product Facility in Singapore

Nov 2020

Global life sciences company, Thermo Fisher Scientific, has announced plans to develop a facility with two new sterile filling lines in Singapore, extending its capacity for developing and manufacturing therapies and vaccines in the Asia Pacific. It will include a high-speed sterile line for live virus filling, a first of such large scale capability in Singapore, and an additional line for standard fill/finish. It will also contain cleanroom capacity, labs, warehousing, and offices.

The facility is expected to cost USD130 million and is estimated to be completed in 2022. Its manufacturing capacity will be up to 30 million sterile doses per month. It will employ over 300 people, giving it the capability to meet regional demand and respond more effectively to future health emergencies. This facility was established with the support of the Singapore Economic Development Board (EDB), highlighting the importance of government and industry collaboration in light of the Covid-19 pandemic, by ensuring the availability of critical diagnostic tests, therapies, and vaccines.

(Source: Drug Discovery and Development)

About Us

Orissa International helps companies that want to develop a market entry strategy for Southeast Asia or implement their business expansion into the region. We have very strong domain knowledge of markets and industry sectors, and a business network of over 16,000 companies that includes distributors, resellers, system integrators and local manufacturers, that we have built through advising and guiding more than 5,000 companies with their market expansion into the ASEAN region over the last 25 years.

Orissa International is headquartered in Singapore, with additional offices in Malaysia, Indonesia, Thailand, Vietnam, and the Philippines.

Our Services